An update on ripasudil for the treatment of glaucoma and ocular hypertension
Copyright 2020 Clarivate Analytics..
Ripasudil (K-115) is a novel Rho-associated protein kinase (ROCK) inhibitor. The Rho-ROCK pathway regulates key downstream effectors involved in many cellular functions, in particular in the actin cytoskeleton activity. The clinical effects of ripasudil expected on the eye include an intraocular pressure-lowering effect and a wound-healing activity on corneal endothelial cells, but many other functions are currently under investigation. To date, ripasudil has been approved in Japan (2014) for the treatment of glaucoma and ocular hypertension, and several clinical trials are currently investigating its role in the treatment of Fuchs' corneal dystrophy. In this review, we will discuss its pharmacokinetics, pharmacodynamics and clinical efficacy, focusing also on its safety and tolerability profile.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:56 |
|---|---|
| Enthalten in: |
Drugs of today (Barcelona, Spain : 1998) - 56(2020), 9 vom: 07. Sept., Seite 599-608 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Testa, V [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
EC 2.7.11.1 |
|---|
| Anmerkungen: |
Date Completed 08.10.2020 Date Revised 08.10.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1358/dot.2020.56.9.3178110 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315961295 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315961295 | ||
| 003 | DE-627 | ||
| 005 | 20231225160039.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1358/dot.2020.56.9.3178110 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1053.xml |
| 035 | |a (DE-627)NLM315961295 | ||
| 035 | |a (NLM)33025953 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Testa, V |e verfasserin |4 aut | |
| 245 | 1 | 3 | |a An update on ripasudil for the treatment of glaucoma and ocular hypertension |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.10.2020 | ||
| 500 | |a Date Revised 08.10.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright 2020 Clarivate Analytics. | ||
| 520 | |a Ripasudil (K-115) is a novel Rho-associated protein kinase (ROCK) inhibitor. The Rho-ROCK pathway regulates key downstream effectors involved in many cellular functions, in particular in the actin cytoskeleton activity. The clinical effects of ripasudil expected on the eye include an intraocular pressure-lowering effect and a wound-healing activity on corneal endothelial cells, but many other functions are currently under investigation. To date, ripasudil has been approved in Japan (2014) for the treatment of glaucoma and ocular hypertension, and several clinical trials are currently investigating its role in the treatment of Fuchs' corneal dystrophy. In this review, we will discuss its pharmacokinetics, pharmacodynamics and clinical efficacy, focusing also on its safety and tolerability profile | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Glaucoma | |
| 650 | 4 | |a Ocular hypertension | |
| 650 | 4 | |a Ophthalmic drugs | |
| 650 | 4 | |a Rho-associated protein kinase (ROCK) inhibitors | |
| 650 | 4 | |a Ripasudil | |
| 650 | 7 | |a Isoquinolines |2 NLM | |
| 650 | 7 | |a K-115 |2 NLM | |
| 650 | 7 | |a Sulfonamides |2 NLM | |
| 650 | 7 | |a rho-Associated Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 700 | 1 | |a Ferro Desideri, L |e verfasserin |4 aut | |
| 700 | 1 | |a Della Giustina, P |e verfasserin |4 aut | |
| 700 | 1 | |a Traverso, C E |e verfasserin |4 aut | |
| 700 | 1 | |a Iester, M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drugs of today (Barcelona, Spain : 1998) |d 1998 |g 56(2020), 9 vom: 07. Sept., Seite 599-608 |w (DE-627)NLM123139600 |x 1699-3993 |7 nnns |
| 773 | 1 | 8 | |g volume:56 |g year:2020 |g number:9 |g day:07 |g month:09 |g pages:599-608 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1358/dot.2020.56.9.3178110 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 56 |j 2020 |e 9 |b 07 |c 09 |h 599-608 | ||